Description: Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Home Page: www.santhera.com
0QN1 Technical Analysis
Hohenrainstrasse 24
Pratteln,
4133
Switzerland
Phone:
41 61 906 89 50
Officers
| Name | Title |
|---|---|
| Dr. Thomas Meier Ph.D. | Founder & Chairman |
| Mr. Dario Eklund | Chief Executive Officer |
| Mr. Andrew P. Smith CGMA, FCMA | Chief Financial Officer |
| Mr. Oliver Strub | Head of Compliance |
| Mr. Günther Metz Ph.D. | Head Business Development |
| Mr. Shabir Hasham M.D. | Chief Medical Officer |
| Mr. Marc Schrader | Chief Technology Officer |
| Dr. Oliver P. Kronenberg | Chief Legal Officer & Corporate Secretary |
| Mr. Neville Kodkani M.D. | Head of Global Marketing & Partner Management |
| Ms. Sarah Holmes-Klotz | Head of People & Culture |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: British Pound (£)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.8016 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |